Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32:65-71. [PMID: 18162772 DOI: 10.1097/PAS.0b013e318058a96b] [Citation(s) in RCA: 245] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]

For:	Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32:65-71. [PMID: 18162772 DOI: 10.1097/PAS.0b013e318058a96b] [Citation(s) in RCA: 245] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]

Number

Cited by Other Article(s)

Pantoja-Romero W, Lavín-Flores A, Morell G, Martínez M, Weiner BR, Coronas J. Solvent-Free Process for Preparing Metal-Organic Framework Composites Based on Carbon-Based Quantum Dots and Their Derivatives as Drug Delivery Systems for Andrographolide. Chemistry 2025:e202500655. [PMID: 40326208 DOI: 10.1002/chem.202500655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2025] [Revised: 04/29/2025] [Accepted: 05/05/2025] [Indexed: 05/07/2025]

Kitahama K, Shigematsu Y, Sugawara E, Amori M, Amori G, Saito R, Ohmoto A, Yonese J, Takeuchi K, Inamura K. Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma. BMC Cancer 2025;25:766. [PMID: 40275187 PMCID: PMC12020276 DOI: 10.1186/s12885-025-14157-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2025] [Accepted: 04/14/2025] [Indexed: 04/26/2025] Open

Abstract

BACKGROUND

Small cell carcinoma (SmCC) of the bladder is a rare and aggressive malignancy. Characterizing transcription factor (TF)-defined subtypes may provide insights into its biology and inform targeted therapies. This study investigates lineage-specific TF expression in bladder SmCC, its association with clinicopathological features, and comparisons with prostate SmCC.

METHODS

A retrospective analysis was conducted on 9 cases of bladder SmCC and 6 cases of prostate SmCC diagnosed at a single cancer hospital in Japan. Immunohistochemistry was performed for lineage-specific TFs (ASCL1, NEUROD1, POU2F3, and YAP1) and neuroendocrine and other markers. Statistical comparisons were made using Fisher's exact test and independent samples t-tests.

RESULTS

Combined SmCC morphology, including urothelial carcinoma (UC) (5 cases) and adenocarcinoma (2 cases), was more frequent in bladder SmCC than in prostate SmCC (78% [7 of 9 cases] vs. 17% [1 of 6 cases], p = 0.041). NEUROD1 was more frequently expressed in bladder SmCC than in prostate SmCC (67% [6 of 9 cases] vs. 0% [0 of 6 cases]; p = 0.028). NEUROD1 expression was more frequent in combined SmCC and UC bladder tumors than in other bladder SmCC tumors (100% [5 of 5 cases] vs. 25% [1 of 4 cases], p = 0.048). Conversely, HNF4A expression was absent in all combined SmCC and UC bladder tumors (0 of 5) but present in 75% (3 of 4) of other bladder SmCC tumors (p = 0.048). In 2 cases of bladder SmCC, NEUROD1 and POU2F3 were expressed in a mutually exclusive manner, with neuroendocrine markers expressed only in the NEUROD1-expressing component.

CONCLUSIONS

NEUROD1 is characteristically expressed in bladder SmCC, especially in SmCC combined with UC, suggesting a distinct phenotype from prostate SmCC. These findings highlight the potential for TF-based classification to improve diagnostic accuracy and inform therapeutic strategies.

Collapse

Affiliation(s)

Keiichiro Kitahama Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan
Yasuyuki Shigematsu Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Emiko Sugawara Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Mahmut Amori Division of Tumor Pathology, Jichi Medical University, Shimotsuke, Japan
Gulanbar Amori Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Division of Tumor Pathology, Jichi Medical University, Shimotsuke, Japan
Rumiko Saito Department of Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Department of Clinical Chemotherapy, The Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan Graduate School of Engineering, Chiba Institute of Technology, Chiba, Japan
Akihiro Ohmoto Department of Medical Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Junji Yonese Department of Genitourinary Oncology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
Kengo Takeuchi Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Pathology Project for Molecular Targets, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan
Kentaro Inamura Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550, Japan. Department of Pathology, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan. Division of Tumor Pathology, Jichi Medical University, Shimotsuke, Japan.

Collapse

Haffner MC, Morris MJ, Ding CKC, Sayar E, Mehra R, Robinson B, True LD, Gleave M, Lotan TL, Aggarwal R, Huang J, Loda M, Nelson PS, Rubin MA, Beltran H. Framework for the Pathology Workup of Metastatic Castration-Resistant Prostate Cancer Biopsies. Clin Cancer Res 2025;31:466-478. [PMID: 39589343 PMCID: PMC11790385 DOI: 10.1158/1078-0432.ccr-24-2061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Revised: 09/18/2024] [Accepted: 11/20/2024] [Indexed: 11/27/2024]

Affiliation(s)

Michael C. Haffner Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
Michael J. Morris Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Chien-Kuang C. Ding Department of Anatomic Pathology, University of California San Francisco, San Francisco, CA, USA
Erolcan Sayar Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Rohit Mehra Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA Michigan Center for Translational Pathology, Ann Arbor, MI, USA Rogel Cancer Center, Michigan Medicine, Ann Arbor, MI, USA
Brian Robinson Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
Lawrence D. True Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA
Martin Gleave Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Tamara L. Lotan Departments of Pathology, Urology, Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA
Rahul Aggarwal Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA, USA
Jiaoti Huang Department of Pathology and Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA
Massimo Loda Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA
Peter S. Nelson Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
Mark A. Rubin Department for BioMedical Research, University of Bern, Bern, Switzerland Bern Center for Precision Medicine, University of Bern and Inselspital, Bern, Switzerland
Himisha Beltran Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Collapse

Furlano K, Keshavarzian T, Biernath N, Fendler A, de Santis M, Weischenfeldt J, Lupien M. Epigenomics-guided precision oncology: Chromatin variants in prostate tumor evolution. Int J Cancer 2025. [PMID: 39853587 DOI: 10.1002/ijc.35327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2024] [Revised: 12/17/2024] [Accepted: 01/02/2025] [Indexed: 01/26/2025]

Ueki H, Jimbo N, Terakawa T, Hara T, Tobe T, Hirata J, Wakita N, Okamura Y, Suzuki K, Bando Y, Chiba K, Teishima J, Nakano Y, Miyake H. Evaluating RB1 and p53 as diagnostic markers in treatment-related neuroendocrine prostate cancer through immunohistochemistry and genomic analysis of RB1 and TP53. Prostate 2024;84:1506-1514. [PMID: 39279246 DOI: 10.1002/pros.24791] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2024] [Revised: 08/06/2024] [Accepted: 08/29/2024] [Indexed: 09/18/2024]

Abstract

BACKGROUND

The diagnosis of treatment-related neuroendocrine prostate cancer (t-NEPC) often involves a pathological assessment and immunohistochemistry (IHC) for neuroendocrine markers. Genomic alterations in RB1 and TP53 are frequently observed in NEPC and are believed to play a crucial role in the transformation of adenocarcinoma to NEPC. In this study, we examined the clinicopathologic, immunohistochemical, and genetic features of patients with t-NEPC to better understand their prognosis and diagnostic utility.

METHODS

This retrospective study reviewed the records of patients diagnosed with t-NEPC at Kobe University Hospital between October 2018 and December 2022. Clinical data, including age, serum neuroendocrine marker levels, and treatment history, were collected. IHC was performed for conventional neuroendocrine markers (synaptophysin, chromogranin A, and CD56) and RB1 and p53 expression. Next-generation sequencing (NGS) was conducted using FoundationOne® CDx to identify mutations in RB1 and TP53.

RESULTS

This study included 20 patients with t-NEPC. The median time from ADT initiation to development was 42.8 months. IHC revealed RB1 loss in 75% of cases and p53 abnormalities in 75% of cases. NGS identified RB1 mutations in 55% and TP53 mutations in 75% of cases. The concordance between NGS and IHC results was high, with 70% (14/20) agreement for RB1/RB1 and 80% (16/20) for p53/TP53. The immunostaining and genomic analysis of RB1/RB1 and p53/TP53 showed abnormal findings for the four negative cases for conventional neuroendocrine markers.

CONCLUSIONS

This study indicated high concordance between IHC and NGS findings for RB1/RB1 and p53/TP53 in t-NEPC. We provide a comprehensive benchmark of NGS performance compared with IHC, and these findings may help increase the diagnostic sensitivity of t-NEPC.

Collapse

Farinea G, Calabrese M, Carfì F, Saporita I, Poletto S, Delcuratolo MD, Turco F, Audisio M, Di Stefano FR, Tucci M, Buttigliero C. Impact of Neuroendocrine Differentiation (NED) on Enzalutamide and Abiraterone Efficacy in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Retrospective Analysis. Cells 2024;13:1396. [PMID: 39195285 PMCID: PMC11352349 DOI: 10.3390/cells13161396] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2024] [Revised: 08/01/2024] [Accepted: 08/10/2024] [Indexed: 08/29/2024] Open

Affiliation(s)

Giovanni Farinea Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Mariangela Calabrese Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Federica Carfì Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Isabella Saporita Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Stefano Poletto Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Marco Donatello Delcuratolo Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Fabio Turco Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland;
Marco Audisio Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Francesco Rosario Di Stefano Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)
Marcello Tucci Department of Medical Oncology, Cardinal Massaia Hospital, 14100 Asti, Italy;
Consuelo Buttigliero Department of Oncology, San Luigi Gonzaga University Hospital, University of Turin, 10043 Orbassano, Italy; (M.C.); (F.C.); (I.S.); (S.P.); (M.D.D.); (M.A.); (F.R.D.S.); (C.B.)

Collapse

Xu P, Yang JC, Chen B, Ning S, Zhang X, Wang L, Nip C, Shen Y, Johnson OT, Grigorean G, Phinney B, Liu L, Wei Q, Corey E, Tepper CG, Chen HW, Evans CP, Dall'Era MA, Gao AC, Gestwicki JE, Liu C. Proteostasis perturbation of N-Myc leveraging HSP70 mediated protein turnover improves treatment of neuroendocrine prostate cancer. Nat Commun 2024;15:6626. [PMID: 39103353 PMCID: PMC11300456 DOI: 10.1038/s41467-024-50459-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 07/11/2024] [Indexed: 08/07/2024] Open

Affiliation(s)

Pengfei Xu Department of Urologic Surgery, University of California, Davis, CA, USA
Joy C Yang Department of Urologic Surgery, University of California, Davis, CA, USA
Bo Chen Department of Urologic Surgery, University of California, Davis, CA, USA Department of Urology, West China Hospital, Sichuan University, Sichuan, China
Shu Ning Department of Urologic Surgery, University of California, Davis, CA, USA
Xiong Zhang Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA, USA
Leyi Wang Department of Urologic Surgery, University of California, Davis, CA, USA Graduate Group in Integrative Pathobiology, University of California, Davis, CA, USA
Christopher Nip Department of Urologic Surgery, University of California, Davis, CA, USA
Yuqiu Shen Department of Urologic Surgery, University of California, Davis, CA, USA
Oleta T Johnson Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
Gabriela Grigorean Proteomics Core Facility, University of California, Davis, CA, USA
Brett Phinney Proteomics Core Facility, University of California, Davis, CA, USA
Liangren Liu Department of Urology, West China Hospital, Sichuan University, Sichuan, China
Qiang Wei Department of Urology, West China Hospital, Sichuan University, Sichuan, China
Eva Corey Department of Urology, University of Washington, Washington, WA, USA
Clifford G Tepper Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA, USA University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA
Hong-Wu Chen Department of Biochemistry and Molecular Medicine, School of Medicine, University of California, Davis, CA, USA University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA
Christopher P Evans Department of Urologic Surgery, University of California, Davis, CA, USA University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA
Marc A Dall'Era Department of Urologic Surgery, University of California, Davis, CA, USA University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA
Allen C Gao Department of Urologic Surgery, University of California, Davis, CA, USA University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA
Jason E Gestwicki Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA
Chengfei Liu Department of Urologic Surgery, University of California, Davis, CA, USA. Graduate Group in Integrative Pathobiology, University of California, Davis, CA, USA. University of California, Davis Comprehensive Cancer Center, Sacramento, CA, USA.

Collapse

Xiao M, Tong W, Xiao X, Pu X, Yi F. Systemic metastases in large cell neuroendocrine prostate cancer: a rare case report and literature review. Front Oncol 2024;14:1398673. [PMID: 38812779 PMCID: PMC11133593 DOI: 10.3389/fonc.2024.1398673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Accepted: 05/02/2024] [Indexed: 05/31/2024] Open

Di Y, Song J, Song Z, Wang Y, Meng L. Prognostic nomogram to predict cancer-specific survival with small-cell carcinoma of the prostate: a multi-institutional study. Front Oncol 2024;14:1349888. [PMID: 38800400 PMCID: PMC11116562 DOI: 10.3389/fonc.2024.1349888] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2024] [Accepted: 04/24/2024] [Indexed: 05/29/2024] Open

Abstract

Objective

The aim of this study is to examine the predictive factors for cancer-specific survival (CSS) in patients diagnosed with Small-Cell Carcinoma of the Prostate (SCCP) and to construct a prognostic model.

Methods

Cases were selected using the Surveillance, Epidemiology, and End Results (SEER) database. The Kaplan-Meier method was utilized to calculate survival rates, while Lasso and Cox regression were employed to analyze prognostic factors. An independent prognostic factor-based nomogram was created to forecast CSS at 12 and 24 months. The model's predictive efficacy was assessed using the consistency index (C-index), calibration curve, and decision curve analysis (DCA) in separate tests.

Results

Following the analysis of Cox and Lasso regression, age, race, Summary stage, and chemotherapy were determined to be significant risk factors (P < 0.05). In the group of participants who received training, the rate of 12-month CSS was 44.6%, the rate of 24-month CSS was 25.5%, and the median time for CSS was 10.5 months. The C-index for the training cohort was 0.7688 ± 0.024. As for the validation cohort, it was 0.661 ± 0.041. According to the nomogram, CSS was accurately predicted and demonstrated consistent and satisfactory predictive performance at both 12 months (87.3% compared to 71.2%) and 24 months (80.4% compared to 71.7%). As shown in the external validation calibration plot, the AUC for 12- and 24-month is 64.6% vs. 56.9% and 87.0% vs. 70.7%, respectively. Based on the calibration plot of the CSS nomogram at both the 12-month and 24-month marks, it can be observed that both the actual values and the nomogram predictions indicate a predominantly stable CSS. When compared to the AJCC staging system, DCA demonstrated a higher level of accuracy in predicting CSS through the use of a nomogram.

Conclusion

Clinical prognostic factors can be utilized with nomograms to forecast CSS in Small-Cell Carcinoma of the Prostate (SCCP).

Collapse

Turnham DJ, Mullen MS, Bullock NP, Gilroy KL, Richards AE, Patel R, Quintela M, Meniel VS, Seaton G, Kynaston H, Clarkson RWE, Phesse TJ, Nelson PS, Haffner MC, Staffurth JN, Pearson HB. Development and Characterisation of a New Patient-Derived Xenograft Model of AR-Negative Metastatic Castration-Resistant Prostate Cancer. Cells 2024;13:673. [PMID: 38667288 PMCID: PMC11049137 DOI: 10.3390/cells13080673] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2023] [Revised: 03/26/2024] [Accepted: 04/10/2024] [Indexed: 04/28/2024] Open

Affiliation(s)

Daniel J. Turnham The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Manisha S. Mullen The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Nicholas P. Bullock The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Kathryn L. Gilroy Cancer Research UK Scotland Institute, Glasgow G61 1BD, UK
Anna E. Richards The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Radhika Patel Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA
Marcos Quintela The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Valerie S. Meniel The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Gillian Seaton The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Howard Kynaston Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK Department of Urology, Cardiff and Vale University Health Board, University Hospital of Wales, Cardiff CF14 4XW, UK
Richard W. E. Clarkson The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK
Toby J. Phesse The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK The Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia
Peter S. Nelson Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA Department of Urology, University of Washington, Seattle, WA 98195, USA Department of Medicine, University of Washington, Seattle, WA 98195, USA
Michael C. Haffner Division of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA 98195, USA
John N. Staffurth Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff CF14 4XN, UK
Helen B. Pearson The European Cancer Stem Cell Research Institute, School of Biosciences, Cardiff University, Hadyn Ellis Building, Cardiff CF24 4HQ, UK

Collapse

Briski LM, Aron M, Epstein JI, Russell DH, Assarzadegan N, Delma KS, O’Dell H, Rodriguez E, Montgomery EA, Kryvenko ON. Patterns of Immunoreactivity with TTF-1 Antibodies 8G7G3/1 and SPT24 Suggest Distinct Immunoprofiles Between Most Pulmonary and Nonpulmonary Small Cell Carcinomas. Int J Surg Pathol 2024;32:230-238. [PMID: 37170625 PMCID: PMC11783247 DOI: 10.1177/10668969231171940] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]

Affiliation(s)

Laurence M. Briski Department of Pathology and Laboratory Medicine, University of Miami Hospital, Miami, FL, USA Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
Manju Aron Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA Department of Urology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Jonathan I. Epstein Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA Department of Urology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA Department of Oncology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Daniel H. Russell Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Naziheh Assarzadegan Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA
Katiana S. Delma Department of Pathology and Laboratory Medicine, University of Miami Hospital, Miami, FL, USA
Henry O’Dell Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
Estelamari Rodriguez Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA Department of Oncology, University of Miami Hospital, Miami, FL, USA
Elizabeth A. Montgomery Department of Pathology and Laboratory Medicine, University of Miami Hospital, Miami, FL, USA Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA
Oleksandr N. Kryvenko Department of Pathology and Laboratory Medicine, University of Miami Hospital, Miami, FL, USA Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA Desai Sethi Urology Institute, University of Miami Miller School of Medicine, Miami, FL, USA Department of Radiation Oncology, University of Miami Hospital, Miami, FL, USA

Collapse

Kouroukli O, Bravou V, Giannitsas K, Tzelepi V. Tissue-Based Diagnostic Biomarkers of Aggressive Variant Prostate Cancer: A Narrative Review. Cancers (Basel) 2024;16:805. [PMID: 38398199 PMCID: PMC10887410 DOI: 10.3390/cancers16040805] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2024] [Revised: 02/10/2024] [Accepted: 02/12/2024] [Indexed: 02/25/2024] Open

Liao RS, Ruan HT, Jang A, Huynh M, Nadal Rios R, Hoffman-Censits JH, Wei S, Mian OY, Barata PC. Emerging Insights in Small-Cell Carcinoma of the Genitourinary Tract: From Diagnosis to Novel Therapeutic Horizons. Am Soc Clin Oncol Educ Book 2024;44:e430336. [PMID: 38176691 DOI: 10.1200/edbk_430336] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2024]

Thomas C. [Role of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) treatment: still standard or exception?]. UROLOGIE (HEIDELBERG, GERMANY) 2023;62:1281-1288. [PMID: 37904040 DOI: 10.1007/s00120-023-02215-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 09/29/2023] [Indexed: 11/01/2023]

Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z, Liu B, Hu C, Xue Y, Xin Z, Yang Y, Li A, Jiang Z, Jing N, Zhu HH, Dong L, Zhu Y, Dong B, Pan J, Wang Q, Xue W. The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer. Nat Commun 2023;14:7794. [PMID: 38016952 PMCID: PMC10684895 DOI: 10.1038/s41467-023-43676-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2023] [Accepted: 11/16/2023] [Indexed: 11/30/2023] Open

Affiliation(s)

Yiyi Ji Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Weiwei Zhang Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Kai Shen Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Ruopeng Su Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Xinyu Liu Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Zehua Ma Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Bo Liu Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Cong Hu Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Yizheng Xue Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Zhixiang Xin Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Yi Yang Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Ang Li Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Zhou Jiang Department of Pathology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Na Jing State Key Laboratory of Oncogenes and Related Genes, Ren Ji Med-X Stem Cell Research Center, Shanghai Cancer Institute & Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Helen He Zhu State Key Laboratory of Oncogenes and Related Genes, Ren Ji Med-X Stem Cell Research Center, Shanghai Cancer Institute & Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Liang Dong Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Yinjie Zhu Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Baijun Dong Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Jiahua Pan Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China
Qi Wang Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China. Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200120, China.
Wei Xue Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, China.

Collapse

Ji Y, Liu B, Chen L, Li A, Shen K, Su R, Zhang W, Zhu Y, Wang Q, Xue W. Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway. Cell Oncol (Dordr) 2023;46:1445-1456. [PMID: 37120492 DOI: 10.1007/s13402-023-00822-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 04/23/2023] [Indexed: 05/01/2023] Open

Weng XT, Lin WL, Pan QM, Chen TF, Li SY, Gu CM. Aggressive variant prostate cancer: A case report and literature review. World J Clin Cases 2023;11:6213-6222. [PMID: 37731555 PMCID: PMC10507546 DOI: 10.12998/wjcc.v11.i26.6213] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Revised: 07/29/2023] [Accepted: 08/15/2023] [Indexed: 09/08/2023] Open

Mohanty SK, Lobo A, Williamson SR, Shah RB, Trpkov K, Varma M, Sirohi D, Aron M, Kandukari SR, Balzer BL, Luthringer DL, Ro J, Osunkoya AO, Desai S, Menon S, Nigam LK, Sardana R, Roy P, Kaushal S, Midha D, Swain M, Ambekar A, Mitra S, Rao V, Soni S, Jain K, Diwaker P, Pattnaik N, Sharma S, Chakrabarti I, Sable M, Jain E, Jain D, Samra S, Vankalakunti M, Mohanty S, Parwani AV, Sancheti S, Kumari N, Jha S, Dixit M, Malik V, Arora S, Munjal G, Gopalan A, Magi-Galluzzi C, Dhillon J. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists. Int J Surg Pathol 2023;31:993-1005. [PMID: 35946087 DOI: 10.1177/10668969221116629] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]

Abstract

Background. Neuroendocrine differentiation in the prostate gland ranges from clinically insignificant neuroendocrine differentiation detected with markers in an otherwise conventional prostatic adenocarcinoma to a lethal high-grade small/large cell neuroendocrine carcinoma. The concept of neuroendocrine differentiation in prostatic adenocarcinoma has gained considerable importance due to its prognostic and therapeutic ramifications and pathologists play a pivotal role in its recognition. However, its awareness, reporting, and resource utilization practice patterns among pathologists are largely unknown. Methods. Representative examples of different spectrums of neuroendocrine differentiation along with a detailed questionnaire were shared among 39 urologic pathologists using the survey monkey software. Participants were specifically questioned about the use and awareness of the 2016 WHO classification of neuroendocrine tumors of the prostate, understanding of the clinical significance of each entity, and use of different immunohistochemical (IHC) markers. De-identified respondent data were analyzed. Results. A vast majority (90%) of the participants utilize IHC markers to confirm the diagnosis of small cell neuroendocrine carcinoma. A majority (87%) of the respondents were in agreement regarding the utilization of type of IHC markers for small cell neuroendocrine carcinoma for which 85% of the pathologists agreed that determination of the site of origin of a high-grade neuroendocrine carcinoma is not critical, as these are treated similarly. In the setting of mixed carcinomas, 62% of respondents indicated that they provide quantification and grading of the acinar component. There were varied responses regarding the prognostic implication of focal neuroendocrine cells in an otherwise conventional acinar adenocarcinoma and for Paneth cell-like differentiation. The classification of large cell neuroendocrine carcinoma was highly varied, with only 38% agreement in the illustrated case. Finally, despite the recommendation not to perform neuroendocrine markers in the absence of morphologic evidence of neuroendocrine differentiation, 62% would routinely utilize IHC in the work-up of a Gleason score 5 + 5 = 10 acinar adenocarcinoma and its differentiation from high-grade neuroendocrine carcinoma. Conclusion. There is a disparity in the practice utilization patterns among the urologic pathologists with regard to diagnosing high-grade neuroendocrine carcinoma and in understanding the clinical significance of focal neuroendocrine cells in an otherwise conventional acinar adenocarcinoma and Paneth cell-like neuroendocrine differentiation. There seems to have a trend towards overutilization of IHC to determine neuroendocrine differentiation in the absence of neuroendocrine features on morphology. The survey results suggest a need for further refinement and development of standardized guidelines for the classification and reporting of neuroendocrine differentiation in the prostate gland.

Collapse

Affiliation(s)

Sambit K Mohanty Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, India
Anandi Lobo Department of Pathology and Laboratory Medicine, Kapoor Urology Center and Pathology Laboratory, Raipur, India
Sean R Williamson Department of Pathology, Cleveland Clinic, Cleveland, OH, USA
Rajal B Shah Department of Pathology, UT Southwestern University, Dallas, TX, USA
Kiril Trpkov Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
Murali Varma Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, UK
Deepika Sirohi Department of Pathology, University of Utah, Salt Lake City, UT, USA
Manju Aron Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
Shivani R Kandukari Department of Pathology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA
Bonnie L Balzer Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Daniel L Luthringer Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Jae Ro Department of Pathology and Genomic Medicine, Methodist Hospital, Houston, TX, USA
Adeboye O Osunkoya Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
Sangeeta Desai Department of Pathology, Tata Memorial Hospital, Mumbai, India
Santosh Menon Department of Pathology, Tata Memorial Hospital, Mumbai, India
Lovelesh K Nigam Department of Pathology and Division of Renal and Urologic Pathology, Lal Pathology Laboratory, New Delhi, India
Rohan Sardana Department of Pathology, Ampath Pathological Laboratory, Hyderabad, India
Paromita Roy Department of Oncopathology, Tata Medical Center, Kolkata, India
Seema Kaushal Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, New Delhi, India
Divya Midha Department of Oncopathology, Tata Medical Center, Kolkata, India
Minakshi Swain Department of Pathology and Laboratory Medicine, Apollo Hospital, Hyderabad, India
Asawari Ambekar Department of Pathology and Laboratory Medicine, Apollo Hospital, Mumbai, India
Suvradeep Mitra Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, India
Vishal Rao Department of Pathology and Laboratory Medicine, Basavatarakam Indo American Cancer Hospital and Research Institute, Hyderabad, India
Shailesh Soni Department of Pathology and Laboratory Medicine, Muljibhai Patel Urological Hospital, Gujarat, India
Kavita Jain Department of Pathology and Laboratory Medicine, Max Superspeciality Hospital, New Delhi, India
Preeti Diwaker Department of Pathology, University College of Medical Sciences, New Delhi, India
Niharika Pattnaik Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, India
Shivani Sharma Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Indranil Chakrabarti Department of Pathology, North Bengal Medical College, Siliguri, India
Mukund Sable Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Bhubaneswar, India
Ekta Jain Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Deepika Jain Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Spinder Samra Department of Pathology, Dubbo Base Hospital, Dubbo, NSW, Australia
Mahesha Vankalakunti Department of Pathology and Laboratory Medicine, Manipal Hospital, Bangalore, India
Subhashis Mohanty Department of Histopathology, SUM Ultimate Medicare, Bhubaneswar, India
Anil V Parwani Department of Pathology, Wexner Medical Center, Ohio State University, Columbus, OH, USA
Sankalp Sancheti Department of Pathology and Laboratory Medicine, Homi Bhabha Cancer Hospital & Research Centre, Punjab (A Unit of Tata Memorial Centre, Mumbai), India
Niraj Kumari Department of Pathology and Laboratory Medicine, All India Institute of Medical Sciences, Raebareli, India
Shilpy Jha Department of Pathology and Laboratory Medicine, Advanced Medical Research Institute, Bhubaneswar, India
Mallika Dixit Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Vipra Malik Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Samriti Arora Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Gauri Munjal Department of Pathology and Laboratory Medicine, CORE Diagnostics, Gurgaon, India
Anuradha Gopalan Department of Pathology, Memorial Sloan Kettering Cancer, New York, NY, USA
Cristina Magi-Galluzzi Department of Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
Jasreman Dhillon Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA

Collapse

Cohen D, Hazut Krauthammer S, Fahoum I, Kesler M, Even-Sapir E. PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies. Eur Radiol 2023;33:6502-6512. [PMID: 37052659 DOI: 10.1007/s00330-023-09619-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 03/07/2023] [Accepted: 03/16/2023] [Indexed: 04/14/2023]

Abstract

Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [18F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with 68Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either 18F or 68Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [18F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [18F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [18F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended. KEY POINTS: • The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data. • When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [18F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand. • When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.

Collapse

Huang Z, Tang Y, Wei Y, Qian J, Kang Y, Wang D, Xu M, Nie L, Chen X, Chen N, Zhou Q. Prognostic Significance of Chromogranin A Expression in the Initial and Second Biopsies in Metastatic Prostate Cancer. J Clin Med 2023;12:jcm12103362. [PMID: 37240468 DOI: 10.3390/jcm12103362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2023] [Revised: 03/27/2023] [Accepted: 05/06/2023] [Indexed: 05/28/2023] Open

Chen L, Ji Y, Li A, Liu B, Shen K, Su R, Ma Z, Zhang W, Wang Q, Zhu Y, Xue W. High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer. Front Oncol 2023;13:1085569. [PMID: 36994207 PMCID: PMC10042075 DOI: 10.3389/fonc.2023.1085569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2022] [Accepted: 02/21/2023] [Indexed: 03/14/2023] Open

Kusakabe M, Taguchi A, Tanikawa M, Wagatsuma R, Yamazaki M, Tsuchimochi S, Toyohara Y, Kawata A, Baba S, Ueno T, Sone K, Mori-Uchino M, Ikemura M, Matsunaga H, Nagamatsu T, Wada-Hiraike O, Kawazu M, Ushiku T, Takeyama H, Oda K, Kawana K, Mano H, Osuga Y. Cells with stem-like properties are associated with the development of HPV18-positive cervical cancer. Cancer Sci 2023;114:885-895. [PMID: 36404139 PMCID: PMC9986059 DOI: 10.1111/cas.15664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2022] [Revised: 10/22/2022] [Accepted: 11/15/2022] [Indexed: 11/22/2022] Open

Affiliation(s)

Misako Kusakabe Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Ayumi Taguchi Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Michihiro Tanikawa Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Ryota Wagatsuma Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.,CBBD-OIL, AIST-Waseda University, Tokyo, Japan
Miki Yamazaki Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.,CBBD-OIL, AIST-Waseda University, Tokyo, Japan
Saki Tsuchimochi Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Yusuke Toyohara Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Akira Kawata Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Satoshi Baba Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Toshihide Ueno Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
Kenbun Sone Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Mayuyo Mori-Uchino Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Masako Ikemura Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Hiroko Matsunaga Research Organization for Nano and Life Innovation, Waseda University, Tokyo, Japan
Takeshi Nagamatsu Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Osamu Wada-Hiraike Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Masahito Kawazu Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
Tetsuo Ushiku Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Haruko Takeyama Department of Life Science and Medical Bioscience, Waseda University, Tokyo, Japan.,CBBD-OIL, AIST-Waseda University, Tokyo, Japan.,Research Organization for Nano and Life Innovation, Waseda University, Tokyo, Japan.,Institute for Advanced Research of Biosystem Dynamics, Waseda Research Institute for Science and Engineering, Waseda University, Tokyo, Japan
Katsutoshi Oda Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Kei Kawana Department of Obstetrics and Gynecology, Nihon University School of medicine, Tokyo, Japan
Hiroyuki Mano Division of Cellular Signaling, National Cancer Center Research Institute, Tokyo, Japan
Yutaka Osuga Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Collapse

Abdulfatah E, Fine SW, Lotan TL, Mehra R. Reprint of: de novo neuroendocrine features in prostate cancer. Hum Pathol 2023;133:115-125. [PMID: 36894369 DOI: 10.1016/j.humpath.2023.02.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 07/01/2022] [Indexed: 03/09/2023]

Kufe D. Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer. Int J Mol Sci 2023;24:3719. [PMID: 36835130 PMCID: PMC9967814 DOI: 10.3390/ijms24043719] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2023] [Revised: 02/11/2023] [Accepted: 02/11/2023] [Indexed: 02/16/2023] Open

Molecular Classification of Extrapulmonary Neuroendocrine Carcinomas With Emphasis on POU2F3-positive Tuft Cell Carcinoma. Am J Surg Pathol 2023;47:183-193. [PMID: 36253891 PMCID: PMC9833113 DOI: 10.1097/pas.0000000000001977] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]

Abstract

Extrapulmonary neuroendocrine carcinomas (EP-NECs) are associated with a poor clinical outcome, and limited information is available on the biology and treatment of EP-NECs. We studied EP-NECs by applying the recent novel findings from studies of pulmonary neuroendocrine carcinomas, including POU2F3, the master regulator of tuft cell variant of small cell lung carcinomas. A cohort of 190 patients with surgically resected EP-NECs or poorly differentiated carcinomas (PDCs) were established. Immunohistochemistry (IHC) for POU2F3 along with ASCL1, NEUROD1, YAP1, and conventional neuroendocrine markers was performed on tissue microarrays. Selected cases with or without POU2F3 expression were subjected to targeted gene expression profiling using nCounter PanCancer Pathway panel. POU2F3-positive tuft cell carcinomas were present in 12.6% of EP-NEC/PDCs, with variable proportions according to organ systems. POU2F3 expression was negatively correlated with the expression levels of ASCL1, NEUROD1, and conventional neuroendocrine markers ( P <0.001), enabling IHC-based molecular classification into ASCL1-dominant, NEUROD1-dominant, POU2F3-dominant, YAP1-dominant, and not otherwise specified subtypes. Compared wih POU2F3-negative cases, POU2F3-positive tuft cell carcinomas showed markedly higher expression levels of PLCG2 and BCL2 , which was also validated in the entire cohort by IHC. In addition to POU2F3, YAP1-positive tumors were a distinct subtype among EP-NEC/PDCs, characterized by unique T-cell inflamed microenvironment. We found rare extrapulmonary POU2F3-positive tumors arising from previously unappreciated cells of origin. Our data show novel molecular pathologic features of EP-NEC/PDCs including potential therapeutic vulnerabilities, thereby emphasizing the need for focusing on unique features of EP-NEC/PDCs.

Collapse

Yabusaki R, Yoshimura K, Taku K, Suzuki M. Prostate cancer recurring as small‐cell carcinoma with a BRCA2 somatic mutation. IJU Case Rep 2022;5:489-492. [PMID: 36341199 PMCID: PMC9626344 DOI: 10.1002/iju5.12523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2022] [Accepted: 07/26/2022] [Indexed: 11/25/2022] Open

Kost Y, Mattis DM, Muskat A, Nazarian R, Amin B, Cheng H, McLellan BN. Cutaneous metastasis as the first sign of small-cell cancer: An unexpected presentation in a patient with concurrent prostate cancer. JAAD Case Rep 2022;26:104-106. [PMID: 35958435 PMCID: PMC9357704 DOI: 10.1016/j.jdcr.2022.05.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open

Abdulfatah E, Fine SW, Lotan T, Mehra R. De Novo Neuroendocrine Features in Prostate Cancer. Hum Pathol 2022;127:112-122. [PMID: 35810832 DOI: 10.1016/j.humpath.2022.07.002] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2022] [Accepted: 07/01/2022] [Indexed: 12/22/2022]

Gopalan A, Al-Ahmadie H, Chen YB, Sarungbam J, Sirintrapun SJ, Tickoo SK, Reuter VE, Fine SW. Neuroendocrine Differentiation in the Setting of Prostatic Carcinoma: Contemporary Assessment of a Consecutive Series. Histopathology 2022;81:246-254. [PMID: 35758203 PMCID: PMC9327588 DOI: 10.1111/his.14707] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Revised: 05/20/2022] [Accepted: 06/05/2022] [Indexed: 11/28/2022]

Single-cell proteomics defines the cellular heterogeneity of localized prostate cancer. Cell Rep Med 2022;3:100604. [PMID: 35492239 PMCID: PMC9044103 DOI: 10.1016/j.xcrm.2022.100604] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 12/30/2021] [Accepted: 03/21/2022] [Indexed: 11/16/2022]

Galea LA, Mow C, Fine SW, Manohar P. Primary Prostatic Carcinoma With De Novo Diffuse Neuroendocrine Differentiation. Int J Surg Pathol 2022;30:232-236. [PMID: 34338584 PMCID: PMC9887995 DOI: 10.1177/10668969211035844] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]

Golestani ZB, Soltani S, Kalantari MR, Ghorbani HR, Aghaee A. Rare Case of Small Cell Metastatic Prostatic Adenocarcinoma, Properly Staged by 68Ga-PSMA PET/CT Scan. Clin Nucl Med 2022;47:e259-e261. [PMID: 35025791 DOI: 10.1097/rlu.0000000000004033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Shi HJ, Fan ZN, Zhang JS, Xiong BB, Wang HF, Wang JS. Small-cell carcinoma of the prostate with negative CD56, NSE, Syn, and CgA indicators: A case report. World J Clin Cases 2022;10:1630-1638. [PMID: 35211603 PMCID: PMC8855255 DOI: 10.12998/wjcc.v10.i5.1630] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/01/2021] [Revised: 11/14/2021] [Accepted: 12/31/2021] [Indexed: 02/06/2023] Open

Singh N, Ramnarine VR, Song JH, Pandey R, Padi SKR, Nouri M, Olive V, Kobelev M, Okumura K, McCarthy D, Hanna MM, Mukherjee P, Sun B, Lee BR, Parker JB, Chakravarti D, Warfel NA, Zhou M, Bearss JJ, Gibb EA, Alshalalfa M, Karnes RJ, Small EJ, Aggarwal R, Feng F, Wang Y, Buttyan R, Zoubeidi A, Rubin M, Gleave M, Slack FJ, Davicioni E, Beltran H, Collins C, Kraft AS. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun 2021;12:7349. [PMID: 34934057 PMCID: PMC8692330 DOI: 10.1038/s41467-021-26901-9] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2019] [Accepted: 10/22/2021] [Indexed: 12/15/2022] Open

Affiliation(s)

Neha Singh University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA
Varune R Ramnarine Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA, 02215, USA
Jin H Song University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, 85724, USA
Ritu Pandey University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, 85724, USA
Sathish K R Padi University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA Department of Molecular Biology and Biophysics, UConn Health Center, Farmington, CT, 06030, USA
Mannan Nouri Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Virginie Olive University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA Department of Medicine, University of Arizona, Tucson, AZ, 85724, USA
Maxim Kobelev Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Koichi Okumura University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA Department of Physiology, University of Arizona, Tucson, AZ, 85724, USA
David McCarthy Ribomed Biotechnologies, Inc., 8821N. 7th St. STE 300, Phoenix, AZ, 85020, USA
Michelle M Hanna Ribomed Biotechnologies, Inc., 8821N. 7th St. STE 300, Phoenix, AZ, 85020, USA
Piali Mukherjee Epigenomics Core Facility, Weill Cornell Medicine, New York, NY, 10065, USA
Belinda Sun Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, 85724, USA
Benjamin R Lee University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA
J Brandon Parker Department of Obstetrics and Gynecology, Division of Reproductive Science in Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
Debabrata Chakravarti Department of Obstetrics and Gynecology, Division of Reproductive Science in Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA
Noel A Warfel University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, 85724, USA
Muhan Zhou University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA
Jeremiah J Bearss University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA
Ewan A Gibb Decipher Biosciences, Inc, Vancouver, BC, Canada
Mohammed Alshalalfa Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94158, USA
R Jefferey Karnes Department of Urology, Mayo Clinic College of Medicine, Rochester, MN, 55905, USA
Eric J Small Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94158, USA
Rahul Aggarwal Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94158, USA
Felix Feng Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, 94158, USA
Yuzhuo Wang Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Ralph Buttyan Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Amina Zoubeidi Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Mark Rubin Department for BioMedical Research, University of Bern, 3008, Bern, Switzerland
Martin Gleave Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
Frank J Slack Harvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA, 02215, USA
Elai Davicioni Decipher Biosciences, Inc, Vancouver, BC, Canada
Himisha Beltran Department of Medical Oncology, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA, 02115, USA
Colin Collins Vancouver Prostate Centre & Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.
Andrew S Kraft University of Arizona Cancer Center, University of Arizona, Tucson, AZ, 85724, USA. Department of Cellular and Molecular Medicine, University of Arizona, Tucson, AZ, 85724, USA.

Collapse

Slabáková E, Kahounová Z, Procházková J, Souček K. Regulation of Neuroendocrine-like Differentiation in Prostate Cancer by Non-Coding RNAs. Noncoding RNA 2021;7:ncrna7040075. [PMID: 34940756 PMCID: PMC8704250 DOI: 10.3390/ncrna7040075] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 11/18/2021] [Accepted: 11/29/2021] [Indexed: 12/21/2022] Open

Kanayama M, Luo J. Delineating the Molecular Events Underlying Development of Prostate Cancer Variants with Neuroendocrine/Small Cell Carcinoma Characteristics. Int J Mol Sci 2021;22:12742. [PMID: 34884545 PMCID: PMC8657721 DOI: 10.3390/ijms222312742] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2021] [Revised: 11/17/2021] [Accepted: 11/19/2021] [Indexed: 12/18/2022] Open

PCK1 regulates neuroendocrine differentiation in a positive feedback loop of LIF/ZBTB46 signalling in castration-resistant prostate cancer. Br J Cancer 2021;126:778-790. [PMID: 34815524 DOI: 10.1038/s41416-021-01631-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2021] [Revised: 10/24/2021] [Accepted: 11/03/2021] [Indexed: 11/09/2022] Open

Taher A, Jensen CT, Yedururi S, Surasi DS, Faria SC, Bathala TK, Mujtaba B, Bhosale P, Wagner-Bartak N, Morani AC. Imaging of Neuroendocrine Prostatic Carcinoma. Cancers (Basel) 2021;13:5765. [PMID: 34830919 PMCID: PMC8616225 DOI: 10.3390/cancers13225765] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 11/07/2021] [Accepted: 11/10/2021] [Indexed: 12/27/2022] Open

Affiliation(s)

Ahmed Taher Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Corey T. Jensen Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Sireesha Yedururi Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Devaki Shilpa Surasi Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA;
Silvana C. Faria Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Tharakeshwar K. Bathala Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Bilal Mujtaba Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Priya Bhosale Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Nicolaus Wagner-Bartak Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)
Ajaykumar C. Morani Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, 1515 Holocombe Blvd., Houston, TX 77030, USA; (A.T.); (C.T.J.); (S.Y.); (S.C.F.); (T.K.B.); (B.M.); (P.B.); (N.W.-B.)

Collapse

Wang Q, Li Z, Yang J, Peng S, Zhou Q, Yao K, Cai W, Xie Z, Qin F, Li H, Chen X, Li K, Huang H. Loss of NEIL3 activates radiotherapy resistance in the progression of prostate cancer. Cancer Biol Med 2021;19:j.issn.2095-3941.2020.0550. [PMID: 34591415 PMCID: PMC9425180 DOI: 10.20892/j.issn.2095-3941.2020.0550] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open

Affiliation(s)

Qiong Wang Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA.,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Zean Li Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Jin Yang Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Department of Radiation Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Shirong Peng Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Qianghua Zhou Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Kai Yao Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China
Wenli Cai Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Zhongqiu Xie Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
Fujun Qin Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
Hui Li Department of Pathology, School of Medicine, University of Virginia, Charlottesville, VA 22908, USA
Xu Chen Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Kaiwen Li Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China
Hai Huang Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.,Department of Urology, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan People's Hospital, Qingyuan 511518, China

Collapse

Wang Y, Wang Y, Ci X, Choi SYC, Crea F, Lin D, Wang Y. Molecular events in neuroendocrine prostate cancer development. Nat Rev Urol 2021;18:581-596. [PMID: 34290447 PMCID: PMC10802813 DOI: 10.1038/s41585-021-00490-0] [Citation(s) in RCA: 95] [Impact Index Per Article: 23.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/07/2021] [Indexed: 02/07/2023]

Park SH, Fong KW, Mong E, Martin MC, Schiltz GE, Yu J. Going beyond Polycomb: EZH2 functions in prostate cancer. Oncogene 2021;40:5788-5798. [PMID: 34349243 PMCID: PMC8487936 DOI: 10.1038/s41388-021-01982-4] [Citation(s) in RCA: 53] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2021] [Revised: 07/20/2021] [Accepted: 07/22/2021] [Indexed: 02/07/2023]

Berchuck JE, Viscuse PV, Beltran H, Aparicio A. Clinical considerations for the management of androgen indifferent prostate cancer. Prostate Cancer Prostatic Dis 2021;24:623-637. [PMID: 33568748 PMCID: PMC8353003 DOI: 10.1038/s41391-021-00332-5] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 12/16/2020] [Accepted: 01/20/2021] [Indexed: 02/01/2023]

Abstract

BACKGROUND

Many systemic therapies for advanced prostate cancer work by disrupting androgen receptor signaling. Androgen indifferent prostate cancer (AIPC) variants, including aggressive variant prostate cancer (AVPC), neuroendocrine prostate cancer (NEPC), and double-negative prostate cancer (DNPC), are increasingly common and often overlapping resistance phenotypes following treatment with androgen receptor signaling inhibitors in men with metastatic castration-resistant prostate cancer and are associated with poor outcomes. Understanding the underlying biology and identifying effective therapies for AIPC is paramount for improving survival for men with prostate cancer.

METHODS

In this review, we summarize the current knowledge on AIPC variants, including our current understanding of the clinical, morphologic, and molecular features as well as current therapeutic approaches. We also explore emerging therapies and biomarkers aimed at improving outcomes for men with AIPC.

RESULTS AND CONCLUSIONS

Establishing consensus definitions, developing novel biomarkers for early and accurate detection, further characterization of molecular drivers of each phenotype, and developing effective therapies will be critical to improving outcomes for men with AIPC. Significant progress has been made toward defining the clinical and molecular characteristics of AVPC, NEPC, and DNPC. Novel diagnostic approaches, including cell-free DNA, circulating tumor cells, and molecular imaging are promising tools for detecting AIPC in clinical practice. Building on previous treatment advances, several clinical trials are underway evaluating novel therapeutic approaches in patients with AIPC informed by an understanding of variant-specific biology. In this review, we discuss how these recent and ongoing studies will help to improve diagnosis, prognosis, and therapy for men with AIPC.

Collapse

AbdullGaffar B, Hotait H. The value of intercluster single cell streaks, triplet signet ring cells, and a two-cell population in urine small cell neuroendocrine carcinoma. Cytopathology 2021;32:700-704. [PMID: 34029408 DOI: 10.1111/cyt.12997] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2020] [Revised: 04/10/2021] [Accepted: 04/26/2021] [Indexed: 01/02/2023]

Bell PD, Huber AR, Agostini-Vulaj D. Clinicopathologic features of metastatic small cell carcinoma of the prostate to the liver: a series of four cases. Diagn Pathol 2021;16:35. [PMID: 33892760 PMCID: PMC8067396 DOI: 10.1186/s13000-021-01096-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Accepted: 04/13/2021] [Indexed: 01/22/2023] Open

Undesirable Status of Prostate Cancer Cells after Intensive Inhibition of AR Signaling: Post-AR Era of CRPC Treatment. Biomedicines 2021;9:biomedicines9040414. [PMID: 33921329 PMCID: PMC8069212 DOI: 10.3390/biomedicines9040414] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2021] [Revised: 04/07/2021] [Accepted: 04/09/2021] [Indexed: 12/19/2022] Open

Galosi AB, Palagonia E, Scarcella S, Cimadamore A, Lacetera V, Delle Fave RF, Antezza A, Dell'Atti L. Detection limits of significant prostate cancer using multiparametric MR and digital rectal examination in men with low serum PSA: Up-date of the Italian Society of Integrated Diagnostic in Urology. ACTA ACUST UNITED AC 2021;93:92-100. [PMID: 33754619 DOI: 10.4081/aiua.2021.1.92] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 02/10/2021] [Indexed: 11/22/2022]

Kryvenko ON. Small Cell-like Change in Central Zone Histology-A New Observation Mimicking Cribriform Intraductal Prostatic Adenocarcinoma. Int J Surg Pathol 2021;29:635-637. [PMID: 33729852 DOI: 10.1177/10668969211003966] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]

Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis 2021;24:81-87. [PMID: 32286548 DOI: 10.1038/s41391-020-0228-0] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 02/29/2020] [Accepted: 03/20/2020] [Indexed: 12/14/2022]

Cheng WC, Wang HJ. Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer. Tzu Chi Med J 2021;33:224-232. [PMID: 34386358 PMCID: PMC8323647 DOI: 10.4103/tcmj.tcmj_220_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Revised: 09/05/2020] [Accepted: 10/06/2020] [Indexed: 11/15/2022] Open

Butler W, Huang J. Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms. PRECISION CLINICAL MEDICINE 2021;4:25-34. [PMID: 33842835 PMCID: PMC8023015 DOI: 10.1093/pcmedi/pbab003] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2021] [Revised: 01/23/2021] [Accepted: 01/24/2021] [Indexed: 12/12/2022] Open